107
Participants
Start Date
December 19, 2018
Primary Completion Date
July 27, 2022
Study Completion Date
April 28, 2025
VAY736
150 mg powder in vial for solution for injection; after reconstitution to 150 mg/mL per vial, a dose of 300 mg
VAY736 Placebo
solution for injection; 0 mg/mL administered as 2 mL s.c. injection
CFZ533
150 mg/mL as concentrate in vial for infusion, administered at a dose of 10 mg/kg as i.v. infusion
CFZ533 Placebo
Placebo as concentrate in vial for infusion, administered at a dose of 10 mg/kg as i.v. infusion
Novartis Investigative Site, Budapest
Novartis Investigative Site, Clayton
Novartis Investigative Site, Debrecen
Novartis Investigative Site, Berlin
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Pessac
Novartis Investigative Site, Taichung
Novartis Investigative Site, Taichung
Novartis Investigative Site, Gwangju
Novartis Investigative Site, Freiburg im Breisgau
Novartis Investigative Site, Moscow
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Nanjing
Novartis Investigative Site, Taichung
Novartis Investigative Site, Guangzhou
Novartis Investigative Site, Yekaterinburg
Novartis Investigative Site, Ramat Gan
Novartis Investigative Site, Ciudad Autonoma de Bs As
Novartis Investigative Site, Prague
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Chuo Ku
Novartis Investigative Site, Shinjuku Ku
Novartis Investigative Site, Shinjuku-ku
Novartis Investigative Site, Bydgoszcz
Novartis Investigative Site, Poznan
Novartis Investigative Site, Warsaw
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Barcelona
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY